<!DOCTYPE html>
<html>
<head>
	<meta charset="UTF-8">
	<title>font testing</title>
	<link href=./fonts/Invention.woff2" rel="stylesheet">
	<link rel='stylesheet' type='text/css' href='style.css'>
    <meta name="viewport" content="width=device-width, initial-scale=1">
</head>
<body>
    <div id="main2">
        <inventiontitle>Moderate COVID-19 in At Risk Adults</inventiontitle>
        <br><br>
        <span1>
            <b>Inspiring innovation through diversity and inclusion</b>
            <br>
            <p>When we bring together people from different backgrounds, the possibility for invention is endless.</p>
            <p>KENILWORTH, N.J. & MIAMI--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that Merck has submitted an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) for molnupiravir, an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in adults who are at risk for progressing to severe COVID-19 and/or hospitalization. The companies are actively working with regulatory agencies worldwide to submit applications for emergency use or marketing authorization in the coming months.</p>
        </span1>
    </div>
</body>
</html>